| E-Folder |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Bankruptcy > Chapter 13 Bankruptcy - What Does that Entail? |
|
E-Folder - Chapter 13 Bankruptcy - What Does that Entail?
Chapter 13 Bankruptcy is a reorganization bankruptcy. It means that the people who decide to fil According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product e for this type of bankruptcy want to clear their debts over a period of three to five year. Ch ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in apter 13 Bankruptcy appeals to those who have non-exempt property that they want to keep hold of lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. and those who want to stop a foreclosure or repossession of property. If the individual has su here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe fficient income that is regular and can pay for their day to day living expenses and have someth d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro ing left over to repay their debt then they can file Chapter 13 Bankruptcy. If their finances do ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc not fall into this category then they can not. The person filing for bankruptcy should provide easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi the court with schedules of assets and liabilities and then within certain time limits they hav nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically e to file a repayment plan. Once the repayment plan has been file in Chapter 13 Bankruptcy proc and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ eeding the creditors have a limited amount of time to object to the plan. If no objections are m ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ade then the debtors and their creditors are bound by the plan. Chapter 13 Bankruptcy will allo ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a w the debtors to keep a property that he has failed to keep up mortgage payments on even if it i dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod s secured. An "automatic stay" is ordered by the court to prevent any foreclosure proceedings to cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin continue and the debtor then has the opportunity to get caught up during the reorgnization peri tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen od. However, if this does not happen then the debtor will be subject to the foreclosure at the e t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel nd of the period. If there is any secured property that has a value less than the debt in quest ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust ion, Chapter 13 bankruptcy allows for the return of the property to creditor. The creditor can t y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products hen sell the property and pocket the proceeds. Secured debts are to be repaid first and then wh . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de en they are dealt with then non-secured debts will be repaid. In Chapter 13 Bankruptcy any unpai elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip d portion of non-secured debts will be discharged after the period of reorganization has passed. tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Attract More Qualified Leads: 5 Ways to Get More and Better Prospects So How Do You Get Paid For Submitting Survey Forms?
|